Loading stock…

CSPC Innovation Pharmaceutical Co., Ltd. (300765) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

CSPC Innovation Pharmaceutical Co., Ltd.

300765Market cap $9.80BPrice $7.0

Country🇨🇳China

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures generic and innovative drugs across oncology, cardiovascular, and neurology, betting big on R&D to shift China's pharma industry away from copycat medicine toward original therapies that compete globally.

In Bastion Portfolios?

52W Return+14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-7%1

Revenue Forecast

Rev CAGR (1y)+147%10

Rev CAGR (3y)+28%10

Rev CAGR (5y)+44%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2-37%2

EPS Growth Y+3-83%1

Quality

Margins

EBIT Margin26%8

Net Income Margin24%8

Free Cash Flow Margin48%10

Debt

Net Debt/EBITDA-2.710

Efficiency

ROE27%9

ROA15%9

Earnings Stability55

GEAR+VERY STRONG92

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)491

P/E Ratio (Forward 3y)3531

P/BV16.31

EV Multiples

EV/EBITDA Fwd411

EV/EBIT Fwd441

Yield

Free Cash Flow Yield3.3%5

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return+39%10

YTD return+31%8

Mid term

Price vs 52wHigh91%9

1 year return+3%5

Long term

3 year return+193%9

5 year return+700%10

Risk Shield

Price Risk

Beta0.29

Volatility68%2

Free Cash Flow

Free Cash Flow Margin48%10

Free Cash Flow Yield3.3%5

Quality

ROCE24%9

Earnings Stability55

Net Debt/EBITDA-2.710

02Growth

Is it actually growing, and how fast?

300765CSPC Innovation Pharmaceutical Co.

Revenue FY25$309M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-7%1

Revenue, next 1Y+147%10

Revenue, next 3Y, CAGR+28%10

Revenue, next 5Y, CAGR+44%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-37%2

EPS growth, FY28E-83%1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue is set to grow 28%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 28%/yr from here.

The runway holds up: revenue is set to grow 44%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 7%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Earnings are set to fall even as revenue grows (EPS about -37%/yr vs revenue 28%/yr).

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

300765CSPC Innovation Pharmaceutical Co.

Total return Current742%

Price return Current709%

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+39%10

YTD return+31%8

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+3%5

3-year return+193%9

5-year return+700%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +193% over three years and +700% over five, ahead of 90% of the market.

It's up 3% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+39%) and so far this year (+31%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on CSPC Innovation Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

300765CSPC Innovation Pharmaceutical Co.

Revenue FY25$309M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-7%1

Revenue, next 1Y+147%10

Revenue, next 3Y, CAGR+28%10

Revenue, next 5Y, CAGR+44%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-37%2

EPS growth, FY28E-83%1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue is set to grow 28%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 28%/yr from here.

The runway holds up: revenue is set to grow 44%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 7%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Earnings are set to fall even as revenue grows (EPS about -37%/yr vs revenue 28%/yr).

BOTTOM LINE

Reaccelerating Grower

A top-tier grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

300765CSPC Innovation Pharmaceutical Co.

Total return Current742%

Price return Current709%

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+39%10

YTD return+31%8

MID & LONG-TERM▾SCORE

% of 52-week high91%9

1-year return+3%5

3-year return+193%9

5-year return+700%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +193% over three years and +700% over five, ahead of 90% of the market.

It's up 3% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+39%) and so far this year (+31%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on CSPC Innovation Pharmaceutical Co., Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community